PDCD1 and non-small cell lung carcinoma: Moreover, studies have reported that Bifidobacterium breve (B. breve) in the gut significantly prolong the median PFS (mPFS) of patients with NSCLC receiving anti–PD-1 immunotherapy combined with chemotherapy, and B. breve may be an effective biomarker for predicting its clinical benefit (44).